Institutional shares held 37.1 Million
29.9K calls
2.3K puts
Total value of holdings $1.05B
$842K calls
$64K puts
Market Cap $1.14B
40,316,100 Shares Out.
Institutional ownership 92.14%
# of Institutions 176


Latest Institutional Activity in AORT

Top Purchases

Q4 2024
Ophir Asset Management Pty LTD Shares Held: 789K ($22.2M)
Q4 2024
Wasatch Advisors Inc Shares Held: 1.04M ($29.4M)
Q4 2024
Principal Financial Group Inc Shares Held: 202K ($5.7M)
Q4 2024
Point72 Asset Management, L.P. Shares Held: 195K ($5.49M)
Q4 2024
First Trust Advisors LP Shares Held: 167K ($4.7M)

Top Sells

Q4 2024
Morgan Stanley Shares Held: 2.36M ($66.5M)
Q4 2024
Dimensional Fund Advisors LP Shares Held: 1.47M ($41.5M)
Q4 2024
Royce & Associates LP Shares Held: 831K ($23.4M)
Q4 2024
First Eagle Investment Management, LLC Shares Held: 592K ($16.7M)
Q4 2024
Balyasny Asset Management LLC Shares Held: 15.3K ($432K)

About AORT

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.


Insider Transactions at AORT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
546K Shares
From 20 Insiders
Grant, award, or other acquisition 533K shares
Exercise of conversion of derivative security 12.4K shares
Sell / Disposition
157K Shares
From 11 Insiders
Open market or private sale 156K shares
Bona fide gift 1.1K shares

Track Institutional and Insider Activities on AORT

Follow ARTIVION, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AORT shares.

Notify only if

Insider Trading

Get notified when an Artivion, Inc. insider buys or sells AORT shares.

Notify only if

News

Receive news related to ARTIVION, INC.

Track Activities on AORT